Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM | Learn More
Logo yposkesi
waves image

Yposkesi presents its latest progress in viral vector production at the Cell & Gene Therapy World Conference in Miami

Yposkesi presented its latest progress in viral vectors production at the Cell & Gene Therapy World Conference in Miami

Corbeil-Essonnes, France, January 26, 2017 – Yposkesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, presented its latest advances in viral vector production processes (AAVs) at the Cell & Gene Therapy World event, « Meet the future of cell & gene therapy » which took place from 22 to 25 January 2017 in Miami, USA.

The international Cell & Gene Therapy World conference, one of the most important event in the sector, gather nearly 1,300 industry professionals from more than 30 countries.

The launch of 3 products on the market in 2017 represents a key step in the field of gene therapy and more than twenty registrations are expected in the next 5 years. The constant increase in the number of products under development will require sufficient production capacity and efficient production processes.

As part of his presentation entitled “Improved Manufacturing Platform for AAV Manufacturing”, Alain Lamproye, CEO of Yposkesi, highlighted the new technological developments made jointly with Généthon. These developments have led to a very significant increase of AAV processes productivity, results of the significant R&D efforts made by Yposkesi.

Viral vectors production for a gene therapy use presents considerable challenges, the improvement of production yields being one of the main ones. This increase of productivity is essential to meet not only the future needs of the industry, but also to drastically reduce production costs.


Link to the Press Release

Created by Yerokhoff Kostyiantine